{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:10:32Z","timestamp":1792440632252,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":70,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Zhengzhou City Medical and Health Science and Technology Innovation Guidance Program Project","award":["2025YLZDJH158"],"award-info":[{"award-number":["2025YLZDJH158"]}]},{"name":"Scientific Research Project of Women and Infants Hospital of Zhengzhou, China","award":["YNKY202409"],"award-info":[{"award-number":["YNKY202409"]}]},{"name":"Henan Medical Science and technology research plan (joint construction) project","award":["No.LHGJ20240175"],"award-info":[{"award-number":["No.LHGJ20240175"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Acute hepatic porphyria is a rare metabolic disorder characterized by life-threatening acute attacks and chronic neurological symptoms. Givosiran is an RNA interference therapeutic approved by the FDA in 2019 to treat AHP by inhibiting hepatic ALAS1 expression. This study aims to provide a comprehensive pharmacovigilance analysis of givosiran to evaluate its safety profile in real-world clinical settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective disproportionality analysis was conducted using the FAERS database (from inception to Q4 2025) and the VigiAccess database (from inception to January 2026). Four algorithms\u2014ROR, PRR, EBGM, and BCPNN\u2014were employed to detect positive signals. Secondary analyses included clinical prioritization of signals and TTO analysis using the Weibull distribution test.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall,1,286 adverse event reports identifying givosiran as the primary suspect were extracted from FAERS, while the external validation using VigiAccess retrieved 1,326 reports. Among the FAERS reports with available data, female patients were more frequently reported, however, most cases lacked gender information. This demographic trend was supported by VigiAccess data, where reports were predominantly from the Americas (1,024 cases) and Europe (297 cases), with females accounting for 189 cases. Disproportionality analysis identified several adverse events consistent with previously recognized risks, including increased blood homocysteine, renal impairment, and pancreatitis. In addition, multiple signals not currently included in the product labeling\u2014such as abdominal pain, seizure, and mental disorder\u2014were consistently detected across both databases and warrant further investigation. Clinical prioritization categorized acute pancreatitis, seizure, abdominal pain, and renal impairment as moderate priority signals. TTO analysis revealed a mean onset of 544.36 days, with a Weibull shape parameter (\u03b2) of 1.01 (95% CI: 0.73\u20131.26), indicating a random failure-type risk pattern where the hazard remains constant over time. Sensitivity analysis excluding several PTs potentially related to the underlying manifestations of acute hepatic porphyria yielded consistent results, with major metabolic, pancreatic, and hepatic signals remaining statistically significant. Validation in VigiAccess identified 35 signals, confirming key risks such as blood homocysteine Increased and pancreatitis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study corroborates the known risks of givosiran, including elevated blood homocysteine and renal impairment, using both the FAERS and VigiAccess databases, and identifies significant associations of givosiran with pancreatitis and seizures. The consistent detection of these signals across two independent databases further supports their credibility. The random failure-type risk pattern indicates that continuous safety monitoring should be maintained throughout the entire treatment course.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-026-04446-8","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T08:45:01Z","timestamp":1781081101000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Adverse events of givosiran in the treatment of acute hepatic porphyria: a pharmacovigilance study using the FAERS and VigiAccess databases"],"prefix":"10.1186","volume":"21","author":[{"given":"Yinpeng","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengqiang","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"4446_CR1","doi-asserted-by":"publisher","first-page":"24","DOI":"10.21037\/tgh-2020-01","volume":"6","author":"B Wang","year":"2021","unstructured":"Wang B. The acute hepatic porphyrias. Transl Gastroenterol Hepatol. 2021;6:24.","journal-title":"Transl Gastroenterol Hepatol"},{"issue":"3","key":"4446_CR2","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.ymgme.2019.04.008","volume":"128","author":"JD Phillips","year":"2019","unstructured":"Phillips JD. Heme biosynthesis and the porphyrias. Mol Genet Metab. 2019;128(3):164\u201377.","journal-title":"Mol Genet Metab"},{"issue":"9","key":"4446_CR3","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1056\/NEJMra1608634","volume":"377","author":"DM Bissell","year":"2017","unstructured":"Bissell DM, Anderson KE, Bonkovsky HL, Porphyria. N Engl J Med. 2017;377(9):862\u201372.","journal-title":"N Engl J Med"},{"issue":"5","key":"4446_CR4","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s40271-018-0319-3","volume":"11","author":"A Simon","year":"2018","unstructured":"Simon A, Pompilus F, Querbes W, et al. Patient perspective on acute intermittent porphyria with frequent attacks: a disease with intermittent and chronic manifestations. Patient. 2018;11(5):527\u201337.","journal-title":"Patient"},{"issue":"9718","key":"4446_CR5","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/S0140-6736(09)61925-5","volume":"375","author":"H Puy","year":"2010","unstructured":"Puy H, Gouya L, Deybach JC, Porphyrias. Lancet. 2010;375(9718):924\u201337.","journal-title":"Lancet"},{"key":"4446_CR6","unstructured":"Wang B, Bissell DM, Hereditary C. 2012 Dec 13 [updated 2022 May 19]. In: Adam MP, Bick S, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews\u00ae [Internet]. Seattle (WA): University of Washington, Seattle; 1993\u20132026."},{"issue":"3","key":"4446_CR7","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1053\/j.gastro.2022.11.034","volume":"164","author":"B Wang","year":"2023","unstructured":"Wang B, Bonkovsky HL, Lim JK, Balwani M. AGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert Review. Gastroenterology. 2023;164(3):484\u201391.","journal-title":"Gastroenterology"},{"issue":"1","key":"4446_CR8","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1182\/hematology.2024000663","volume":"2024","author":"AK Dickey","year":"2024","unstructured":"Dickey AK, Leaf RK. Givosiran: a targeted treatment for acute intermittent porphyria. Hematol Am Soc Hematol Educ Program. 2024;2024(1):426\u201333.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"6","key":"4446_CR9","doi-asserted-by":"publisher","first-page":"675","DOI":"10.3390\/ph15060675","volume":"15","author":"S Chiappini","year":"2022","unstructured":"Chiappini S, Vickers-Smith R, Guirguis A, Corkery JM, Martinotti G, Harris DR, Schifano F. Pharmacovigilance Signals of the Opioid Epidemic over 10 Years: Data Mining Methods in the Analysis of Pharmacovigilance Datasets Collecting Adverse Drug Reactions (ADRs) Reported to EudraVigilance (EV) and the FDA Adverse Event Reporting System (FAERS). Pharmaceuticals (Basel). 2022;15(6):675.","journal-title":"Pharmaceuticals (Basel)"},{"key":"4446_CR10","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.ajo.2025.05.007","volume":"277","author":"M Lakhani","year":"2025","unstructured":"Lakhani M, Kwan ATH, Mihalache A, et al. Association of Glucagon-Like Peptide-1 Receptor Agonists With Optic Nerve and Retinal Adverse Events: A Population-Based Observational Study Across 180 Countries. Am J Ophthalmol. 2025;277:148\u201368.","journal-title":"Am J Ophthalmol"},{"key":"4446_CR11","doi-asserted-by":"publisher","first-page":"487","DOI":"10.7150\/ijms.8.487","volume":"8","author":"T Sakaeda","year":"2011","unstructured":"Sakaeda T, Kadoyama K, Okuno Y. Adverse event profiles of platinum agents: data mining of the public version of the FDA adverse event reporting system, AERS, and reproducibility of clinical observations. Int J Med Sci. 2011;8:487\u201391.","journal-title":"Int J Med Sci"},{"key":"4446_CR12","doi-asserted-by":"publisher","first-page":"e13331","DOI":"10.1111\/ijcp.13331","volume":"73","author":"L Meng","year":"2019","unstructured":"Meng L, Huang J, Jia Y, Huang H, Qiu F, Sun S. Assessing fluoroquinolone-associated aortic aneurysm and dissection: data mining of the public version of the FDA adverse event reporting system. Int J Clin Pract. 2019;73:e13331.","journal-title":"Int J Clin Pract"},{"issue":"6","key":"4446_CR13","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40264-024-01421-9","volume":"47","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli M, Salvo F, Begaud B, et al. The Reporting of a Disproportionality Analysis for Drug Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Development and Statement. Drug Saf. 2024;47(6):575\u201384.","journal-title":"Drug Saf"},{"key":"4446_CR14","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1177\/0962280211403602","volume":"22","author":"I Zorych","year":"2013","unstructured":"Zorych I, Madigan D, Ryan P, Bate A. Disproportionality methods for pharmacovigilance in longitudinal observational databases. Stat Methods Med Res. 2013;22:39\u201356.","journal-title":"Stat Methods Med Res"},{"issue":"4","key":"4446_CR15","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","volume":"54","author":"A Bate","year":"1998","unstructured":"Bate A, Edwards IR, Lindquist M, Olsson S, Orre R, Lansner A, De Freitas RM. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol. 1998;54(4):315\u201321.","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"4446_CR16","doi-asserted-by":"publisher","first-page":"e0157753","DOI":"10.1371\/journal.pone.0157753","volume":"11","author":"R B\u00f6hm","year":"2016","unstructured":"B\u00f6hm R, von Hehn L, Herdegen T, Klein HJ, Bruhn O, Petri H, H\u00f6cker J. OpenVigil FDA - Inspection of U.S. American Adverse Drug Events Pharmacovigilance Data and Novel Clinical Applications. PLoS ONE. 2016;11(6):e0157753.","journal-title":"PLoS ONE"},{"issue":"04","key":"4446_CR17","first-page":"1394","volume":"26","author":"W Chen","year":"2009","unstructured":"Chen W, Li C, Jiang J. Study on Adverse drug reaction signal detection and automatic warning technology based on BCPNN method. Appl Res Computers. 2009;26(04):1394\u20137. (in Chinese).","journal-title":"Appl Res Computers"},{"key":"4446_CR18","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJ Evans","year":"2001","unstructured":"Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001;10:483\u20136.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"4446_CR19","doi-asserted-by":"crossref","unstructured":"Van Puijenbroek EP, Bate A, Leufkens HG, Lindquist M, Orre R, Egberts AC. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002 Jan-Feb;11(1):3\u201310.","DOI":"10.1002\/pds.668"},{"issue":"6","key":"4446_CR20","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","volume":"18","author":"A Bate","year":"2009","unstructured":"Bate A, Evans SJ. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009;18(6):427\u201336.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"4446_CR21","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s11523-024-01058-9","volume":"19","author":"S Cecco","year":"2024","unstructured":"Cecco S, Puligheddu S, Fusaroli M, Gerratana L, Yan M, Zamagni C, De Ponti F, Raschi E. Emerging Toxicities of Antibody-Drug Conjugates for Breast Cancer: Clinical Prioritization of Adverse Events from the FDA Adverse Event Reporting System. Target Oncol. 2024;19(3):435\u201345.","journal-title":"Target Oncol"},{"issue":"24","key":"4446_CR22","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1056\/NEJMoa1913147","volume":"382","author":"M Balwani","year":"2020","unstructured":"Balwani M, Sardh E, Ventura P, Peir\u00f3 PA, Rees DC, St\u00f6lzel U, Bissell DM, Bonkovsky HL, Windyga J, Anderson KE, Parker C, Silver SM, Keel SB, Wang JD, Stein PE, Harper P, Vassiliou D, Wang B, Phillips J, Ivanova A, Langendonk JG, Kauppinen R, Minder E, Horie Y, Penz C, Chen J, Liu S, Ko JJ, Sweetser MT, Garg P, Vaishnaw A, Kim JB, Simon AR, Gouya L. ENVISION Investigators. Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria. N Engl J Med. 2020;382(24):2289\u2013301.","journal-title":"N Engl J Med"},{"key":"4446_CR23","first-page":"101076","volume":"39","author":"I Redonnet-Vernhet","year":"2024","unstructured":"Redonnet-Vernhet I, Merci\u00e9 P, Lebreton L, Blouin JM, Bronnimann D, Mesli S, Guibet C, Ribeiro E, Gensous N, Duffau P, Gouya L, Richard E. Preventing hyperhomocysteinemia using vitamin B6 supplementation in Givosiran-treated acute intermittent porphyria: Highlights from a case report and brief literature review. Mol Genet Metab Rep. 2024;39:101076.","journal-title":"Mol Genet Metab Rep"},{"issue":"12","key":"4446_CR24","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.3390\/diagnostics11122324","volume":"11","author":"A Ricci","year":"2021","unstructured":"Ricci A, Guida CC, Manzini P, Cuoghi C, Ventura P. Kidney Involvement in Acute Hepatic Porphyrias: Pathophysiology and Diagnostic Implications. Diagnostics (Basel). 2021;11(12):2324.","journal-title":"Diagnostics (Basel)"},{"issue":"6","key":"4446_CR25","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1056\/NEJMoa1807838","volume":"380","author":"E Sardh","year":"2019","unstructured":"Sardh E, Harper P, Balwani M, Stein P, Rees D, Bissell DM, Desnick R, Parker C, Phillips J, Bonkovsky HL, Vassiliou D, Penz C, Chan-Daniels A, He Q, Querbes W, Fitzgerald K, Kim JB, Garg P, Vaishnaw A, Simon AR, Anderson KE. Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent Porphyria. N Engl J Med. 2019;380(6):549\u201358.","journal-title":"N Engl J Med"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-026-04446-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04446-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04446-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T22:23:20Z","timestamp":1787091800000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-026-04446-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4446"],"URL":"https:\/\/doi.org\/10.1186\/s13023-026-04446-8","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"assertion":[{"value":"30 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Generative AI was not employed in any capacity during the preparation or finalization of this manuscript.","order":3,"name":"Ethics","label":"Generative AI statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest that may have influenced the research or its findings, and confirm the absence of any relevant commercial or financial relationships.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"284"}}